Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Bronchopulmonary dysplasia: how can we improve its outcomes?

  • Sung, Tae-Jung (Department of Pediatrics, Hallym University Medical Center)
  • 투고 : 2019.02.19
  • 심사 : 2019.05.17
  • 발행 : 2019.10.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bronchopulmonary dysplasia (BPD) is a chronic lung disease of preterm infants with multiple factors affected from prenatal to postnatal periods. Despite significant advances in neonatal care over almost 50 years, BPD rates have not decreased; in fact, they may have even increased. Since more preterm infants, even at periviable gestational age, survive today, different stages of lung development affect the pathogenesis of BPD. Hence, the definition of BPD has changed from "old" to "new." In this review, we discuss the various definitions of BPD, risk factors from the prenatal to postnatal periods, management strategies by phase, and future directions for research.

키워드

참고문헌

  1. McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI Workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc 2014;11 Suppl 3:S146-53. https://doi.org/10.1513/AnnalsATS.201312-424LD
  2. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68. https://doi.org/10.1056/NEJM196702162760701
  3. Javaid A, Morris I. Bronchopulmonary dysplasia. Pediatr Child Health 2018;28:22-7. https://doi.org/10.1016/j.paed.2017.10.004
  4. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005;146:469-73. https://doi.org/10.1016/j.jpeds.2004.12.023
  5. Berger TM, Bachmann II, Adams M, Schubiger G. Impact of improved survival of very low-birth-weight infants on incidence and severity of bronchopulmonary dysplasia. Biol Neonate 2004;86:124-30. https://doi.org/10.1159/000078953
  6. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015;314:1039-51. https://doi.org/10.1001/jama.2015.10244
  7. Jo HS, Cho KH, Cho SI, Song ES, Kim BI. Recent changes in the incidence of bronchopulmonary dysplasia among very-low-birth-weight infants in Korea. J Korean Med Sci 2015;30 Suppl 1:S81-7. https://doi.org/10.3346/jkms.2015.30.S1.S81
  8. Jobe AH, Steinhorn R. Can we define bronchopulmonary dysplasia? J Pediatr 2017;188:19-23. https://doi.org/10.1016/j.jpeds.2017.06.064
  9. Hines D, Modi N, Lee SK, Isayama T, Sjors G, Gagliardi L, et al. Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. Acta Paediatr 2017;106:366-74. https://doi.org/10.1111/apa.13672
  10. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-32.
  11. Tooley WH. Epidemiology of bronchopulmonary dysplasia. J Pediatr 1979;95(5 Pt 2):851-8. https://doi.org/10.1016/S0022-3476(79)80451-5
  12. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003;23:451-6. https://doi.org/10.1038/sj.jp.7210963
  13. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9. https://doi.org/10.1164/ajrccm.163.7.2011060
  14. Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998;29:710-7. https://doi.org/10.1016/S0046-8177(98)90280-5
  15. Aukland SM, Rosendahl K, Owens CM, Fosse KR, Eide GE, Halvorsen T. Neonatal bronchopulmonary dysplasia predicts abnormal pulmonary HRCT scans in long-term survivors of extreme preterm birth. Thorax 2009;64:405-10. https://doi.org/10.1136/thx.2008.103739
  16. Sung TJ, Hwang SM, Kim MY, Park SG, Choi KY. Relationship between clinical severity of "new" bronchopulmonary dysplasia and HRCT abnormalities in VLBW infants. Pediatr Pulmonol 2018;53: 1391-8. https://doi.org/10.1002/ppul.24121
  17. Dumpa V, Bhandari V. Surfactant, steroids and non-invasive ventilation in the prevention of BPD. Semin Perinatol 2018;42:444-52. https://doi.org/10.1053/j.semperi.2018.09.006
  18. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr 2017;181:12-28.e1. https://doi.org/10.1016/j.jpeds.2016.10.082
  19. Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics 2009;123:1562-73. https://doi.org/10.1542/peds.2008-1962
  20. Savani RC. Modulators of inflammation in bronchopulmonary dysplasia. Semin Perinatol 2018;42:459-70. https://doi.org/10.1053/j.semperi.2018.09.009
  21. Choi CW. Chorioamnionitis: is a major player in the development of bronchopulmonary dysplasia? Korean J Pediatr 2017;60:203-7. https://doi.org/10.3345/kjp.2017.60.7.203
  22. Kallapur SG, Jobe AH. Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed 2006;91:F132-5. https://doi.org/10.1136/adc.2004.068544
  23. Haye NL, Hutten MC, Kunzman S, Kramer BW. Bronchopulmonary dysplasia and Ureaplasma: what do we know so far? Neonatal Medicine 2017;24:1-6. https://doi.org/10.5385/nm.2017.24.1.1
  24. Sung TJ. Ureaplasma infections in pre-term infants: Recent information regarding the role of Ureaplasma species as neonatal pathogens. Korean J Pediatr 2010;53:989-93. https://doi.org/10.3345/kjp.2010.53.12.989
  25. Sorensen GL, Dahl M, Tan Q, Bendixen C, Holmskov U, Husby S. Surfactant protein-D-encoding gene variant polymorphisms are linked to respiratory outcome in premature infants. J Pediatr 2014; 165:683-9. https://doi.org/10.1016/j.jpeds.2014.05.042
  26. Winters AH, Levan TD, Vogel SN, Chesko KL, Pollin TI, Viscardi RM. Single nucleotide polymorphism in toll-like receptor 6 is associated with a decreased risk for ureaplasma respiratory tract colonization and bronchopulmonary dysplasia in preterm infants. Pediatr Infect Dis J 2013;32:898-904. https://doi.org/10.1097/inf.0b013e31828fc693
  27. Bhandari V, Bizzarro MJ, Shetty A, Zhong X, Page GP, Zhang H, et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006;117:1901-6 https://doi.org/10.1542/peds.2005-1414
  28. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997;42:348-55. https://doi.org/10.1203/00006450-199709000-00016
  29. Naik AS, Kallapur SG, Bachurski CJ, Jobe AH, Michna J, Kramer BW, et al. Effects of ventilation with different positive end-expiratory pressures on cytokine expression in the preterm lamb lung. Am J Respir Crit Care Med 2001;164:494-8. https://doi.org/10.1164/ajrccm.164.3.2010127
  30. Kim SH, Chun J, Ko KH, Sung TJ. Effect of antenatal azithromycin for Ureaplasma spp. on neonatal outcome at $\leq{30}$ weeks' gestational age. Pediatr Int 2019;61:58-62. https://doi.org/10.1111/ped.13738
  31. Sung TJ, Lee KY, Ju YS. Effects of maternal cervical incompetence on morbidity and mortality of very low birthweight neonates. Neonatology 2010;98:164-9. https://doi.org/10.1159/000282112
  32. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017;3:CD004454.
  33. Birenbaum HJ, Dentry A, Cirelli J, Helou S, Pane MA, Starr K, et al. Reduction in the incidence of chronic lung disease in very low birth weight infants: results of a quality improvement process in a tertiary level neonatal intensive care unit. Pediatrics 2009;123:44-50. https://doi.org/10.1542/peds.2007-2872
  34. Foglia EE, Jensen EA, Kirpalani H. Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants. J Perinatol 2017;37:1171-9. https://doi.org/10.1038/jp.2017.74
  35. Bhandari V. The potential of non-invasive ventilation to decrease BPD. Semin Perinatol 2013;37:108-14. https://doi.org/10.1053/j.semperi.2013.01.007
  36. Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2016;(6):CD001243.
  37. Kribs A. Minimally invasive surfactant therapy and noninvasive respiratory support. Clin Perinatol 2016;43:755-71. https://doi.org/10.1016/j.clp.2016.07.010
  38. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003;349:959-67. https://doi.org/10.1056/NEJMoa023080
  39. Hunt K, Dassios T, Ali K, Greenough A. Volume targeting levels and work of breathing in infants with evolving or established bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 2019;104: F46-9. https://doi.org/10.1136/archdischild-2017-314308
  40. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, et al. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. J Pediatr 2014;164:34-9.e2. https://doi.org/10.1016/j.jpeds.2013.07.027
  41. Onland W, Cools F, Kroon A, Rademaker K, Merkus MP, Dijk PH, et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA 2019;321:354-63. https://doi.org/10.1001/jama.2018.21443
  42. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;10:CD001146.
  43. Onland W, Offringa M, van Kaam A. Late ($\geq$ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;8:CD002311.
  44. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:217-24. https://doi.org/10.1159/000286210
  45. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 2016;387:1827-36. https://doi.org/10.1016/S0140-6736(16)00202-6
  46. Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 2015;373:1497-506. https://doi.org/10.1056/NEJMoa1501917
  47. Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D. Inhaled corticosteroids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics 2016;138. pii: e20162511.
  48. Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med 2016;193:86-95. https://doi.org/10.1164/rccm.201505-0861OC
  49. Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Pulmonol 2017;52:968-75. https://doi.org/10.1002/ppul.23680
  50. Poindexter BB, Martin CR. Impact of nutrition on bronchopulmonary dysplasia. Clin Perinatol 2015;42:797-806. https://doi.org/10.1016/j.clp.2015.08.007
  51. Donn SM. Bronchopulmonary dysplasia: myths of pharmacologic management. Semin Fetal Neonatal Med 2017;22:354-8. https://doi.org/10.1016/j.siny.2017.08.002
  52. Papagianis PC, Pillow JJ, Moss TJ. Bronchopulmonary dysplasia: pathophysiology and potential anti-inflammatory therapies. Paediatr Respir Rev 2019;30:34-41.
  53. Alvarez-Fuente M, Moreno L, Mitchell JA, Reiss IK, Lopez P, Elorza D, et al. Preventing bronchopulmonary dysplasia: new tools for an old challenge. Pediatr Res 2019;85:432-41. https://doi.org/10.1038/s41390-018-0228-0
  54. Guillen U, Weiss EM, Munson D, Maton P, Jefferies A, Norman M, et al. Guidelines for the management of extremely premature deliveries: a systematic review. Pediatrics 2015;136:343-50. https://doi.org/10.1542/peds.2015-0542
  55. Patel RM, Rysavy MA, Bell EF, Tyson JE. Survival of infants born at periviable gestational ages. Clin Perinatol 2017;44:287-303. https://doi.org/10.1016/j.clp.2017.01.009
  56. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr 2018;197:300-8. https://doi.org/10.1016/j.jpeds.2018.01.043

피인용 문헌

  1. Strategies to improve outcomes of bronchopulmonary dysplasia vol.62, pp.10, 2019, https://doi.org/10.3345/kjp.2019.00661
  2. Mechanism of oxidative stress and Keap-1/Nrf2 signaling pathway in bronchopulmonary dysplasia vol.99, pp.26, 2019, https://doi.org/10.1097/md.0000000000020433
  3. Comparisons of two definitions of bronchopulmonary dysplasia for the premature infants vol.57, pp.1, 2019, https://doi.org/10.1002/ppul.25739